A young Auckland real estate agent is battling stage 3 cervical cancer after a misread smear test delayed her diagnosis by a year. Such stories highlight the inherent risk of using ageing methodologies with subjective human interpretation to screen for cervical cancer.

View TruScreen’s Annual Shareholder Meeting presentation, delivered today by Martin Dillon, CEO.

An update on the implementation of our strategy to engage with Ministries of Health, Non-Government Organizations (NGO’s) and private foundations funding public screening programs in emerging markets.

The Share Purchase Plan announced on 29 May 2025 closed oversubscribed raising ~NZ$1.67 million (~83 million shares at NZ$0.02).

View TruScreen’s Annual Report 2025.

Uzbekistan regulatory approval received; Zimbabwe validation to be completed 21 July; First TruScreen order from India landed; TruScreen’s Superiority Confirmed in Beijing Study.

Truscreen is pleased to advise that the Company has received firm commitments from both new and existing investors for an initial Placement of 107,034,091 shares at NZ$0.022/A$0.02 each to raise NZ$2,354,750, before costs.

Following a year of significant progress growing our geographic distribution capability (India and Indonesia, among others) and product suite (Dalton Bio HPV IVD products), TruScreen is seeking approximately NZ$3m through Placement, Share Purchase Plan and Options to fund further growth.

TruScreen is pleased to announce that an Agreement has been signed with Hangzhou Dalton Bioscience Limited (“DaltonBio”), for TruScreen to distribute DaltonBio’s HPV-related In Vitro Diagnostics (“IVD”) products in India.

Truscreen Group Limited (NZX/ASX: TRU) (the Company) has released its preliminary unaudited financial results for the year ended 31 March 2025.

Published Saudi Arabia study confirms TruScreen’s high sensitivity and specificity compared to pap smear.

TruScreen re-enters India and appoints Renovate Biologicals Pvt Ltd to distribute its AI enabled TruScreen cervical cancer screening system in India.

Marty Dillon, TruScreen CEO, is presenting the company’s innovative AI enabled cervical cancer screening technology at the Singapore Healthcare Day Forum.

TruScreen is pleased to share an updated Investor Presentation as at March 2025.

TruScreen Group Limited (NZX/ASX:TRU) is pleased to provide an update of its key markets and target markets.

TruScreen Group Limited has signed a non-binding Memorandum of Understanding (“MOU”) with Hangzhou Dalton Bioscience Limited (“DaltonBio”), a leading China based manufacturer of high-performance HPV DNA tests and laboratory equipment for cervical cancer screening.

TruScreen appoints PT Mawar Mitra Medika to distribute its AI enabled TruScreen cervical cancer screening system in Indonesia.

TruScreen had presented at a World Health Organisation (WHO) global meeting to further the use of AI technologies for screening of cervical cancer.